M 3814

Drug Profile

M 3814

Alternative Names: M-3814; MSC-2490484A

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck KGaA
  • Developer EMD Serono Research & Development Institute; Merck KGaA
  • Class Antineoplastics; Small molecules
  • Mechanism of Action DNA activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Small cell lung cancer
  • Phase I Chronic lymphocytic leukaemia; Solid tumours

Most Recent Events

  • 29 Jun 2017 Merck completes a phase I trial in Solid tumours and Chronic lymphocytic leukaemia (Late-stage disease) in Germany (PO) (NCT02316197)
  • 02 Jun 2017 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Solid tumours and Chronic lymphocytic leukaemia presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 02 Jun 2017 Adverse events data from phase Ia of a phase Ia/Ib trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top